Literature DB >> 32970483

21 Code of Federal Regulations Part 11-Compliant Digital Signature Solution for Cancer Clinical Trials: A Single-Institution Feasibility Study.

Therica M Miller1, Jenny Lester2, Lorna Kwan3, Megha D Tandel3, Beth Y Karlan2, B J Rimel4.   

Abstract

PURPOSE: Inefficiencies in the clinical trial infrastructure result in protracted trial completion timelines, physician-investigator turnover, and a shrinking skilled labor force and present obstacles to research participation. Taken together, these barriers hinder scientific progress. Technological solutions to improve clinical trial efficiency have emerged, yet adoption remains slow because of concerns with cost, regulatory compliance, and implementation.
METHODS: A prospective pilot study that compared regulatory-compliant digital and traditional wet ink paper signatures was conducted over a 6.5-month period in a hospital-based health system. Staff time and effort, error rate, costs, and time to completion were measured. Wilcoxon rank sum tests were used to compare staff time and time to completion. A value analysis was conducted. A survey was administered to measure user satisfaction.
RESULTS: There where 96 participants (47 digital, 49 paper), 132 studies included (31 digital, 101 paper), and 265 documents processed (156 digital, 109 paper). A moderate reduction in staff time required to prepare documents for signature was observed (P < .0001). Error rates were reported in 5.1% of digital and 2.8% of paper documents, but this difference was not significant. Discrepancies requiring revisions included incomplete mandatory fields, inaccurate information submitted, and technical issues. A value analysis demonstrated a 19% labor savings with the use of digital signatures. Survey response rate was 57.4% (n = 27). Most participants (85.2%) preferred digital signatures. The time to complete documents was faster with digital signatures compared with paper (P = .0241).
CONCLUSION: The use of digital signatures resulted in a decrease in document completion time and regulatory burden as represented by staff hours. Additional cost and time savings and information liquidity could be realized by integrating digital signatures and electronic document management systems.

Entities:  

Year:  2020        PMID: 32970483      PMCID: PMC7529516          DOI: 10.1200/CCI.20.00027

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  10 in total

1.  Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.

Authors:  David M Dilts; Alan B Sandler; Steven K Cheng; Joshua S Crites; Lori B Ferranti; Amy Y Wu; Shanda Finnigan; Steven Friedman; Margaret Mooney; Jeffrey Abrams
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

2.  A "three-plus-one" evaluation model for clinical research management.

Authors:  David M Dilts
Journal:  Eval Health Prof       Date:  2013-08-01       Impact factor: 2.651

3.  Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement.

Authors:  Karen M Winkfield; Jonathan K Phillips; Steven Joffe; Michael T Halpern; Dana S Wollins; Beverly Moy
Journal:  J Clin Oncol       Date:  2018-09-13       Impact factor: 44.544

4.  Assessing the impact of protocol design changes on clinical trial performance.

Authors:  Kenneth A Getz; Julia Wenger; Rafael A Campo; Edward S Seguine; Kenneth I Kaitin
Journal:  Am J Ther       Date:  2008 Sep-Oct       Impact factor: 2.688

5.  Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.

Authors:  David M Dilts; Alan B Sandler
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

6.  A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.

Authors:  Steven K Cheng; Mary S Dietrich; David M Dilts
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

7.  Sustaining the Clinical and Translational Research Workforce: Training and Empowering the Next Generation of Investigators.

Authors:  Helen L Yin; Janice Gabrilove; Rebecca Jackson; Carol Sweeney; Alecia M Fair; Robert Toto
Journal:  Acad Med       Date:  2015-07       Impact factor: 6.893

8.  The Impact of Protocol Amendments on Clinical Trial Performance and Cost.

Authors:  Kenneth A Getz; Stella Stergiopoulos; Mary Short; Leon Surgeon; Randy Krauss; Sybrand Pretorius; Julian Desmond; Derek Dunn
Journal:  Ther Innov Regul Sci       Date:  2016-07       Impact factor: 1.778

9.  Incentive and Reminder Strategies to Improve Response Rate for Internet-Based Physician Surveys: A Randomized Experiment.

Authors:  David A Cook; Christopher M Wittich; Wendlyn L Daniels; Colin P West; Ann M Harris; Timothy J Beebe
Journal:  J Med Internet Res       Date:  2016-09-16       Impact factor: 5.428

10.  One and done: Reasons principal investigators conduct only one FDA-regulated drug trial.

Authors:  Amy Corneli; Christine Pierre; Terri Hinkley; Li Lin; Christopher B Fordyce; Gerrit Hamre; Matthew T Roe
Journal:  Contemp Clin Trials Commun       Date:  2017-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.